Multicomponent nanoparticles as nonviral vectors for the treatment of Fabry disease by gene therapy

作者：Perez Ruiz de Garibay Aritz; Delgado Diego; del Pozo Rodriguez Ana; Angeles Solinis Maria; Rodriguez Gascon Alicia

来源：Drug Design, Development and Therapy, 2012, 6: 303-310.

DOI：10.2147/DDDT.S36131

• solid lipid nanoparticles
• Fabry disease
• nonviral vectors
• gene therapy

Purpose: Gene-mediated enzyme replacement is a reasonable and highly promising approach for the treatment of Fabry disease (FD). The objective of the present study was to demonstrate the potential applications of solid lipid nanoparticle (SLN)-based nonviral vectors for the treatment of FD. %26lt;br%26gt;Methods: SLNs containing the pR-M10-alpha Gal A plasmid that encodes the alpha-Galactosidase A (alpha-Gal A) enzyme were prepared and their in vitro transfection efficacy was studied in Hep G2 cells. We also studied the cellular uptake of the vectors and the intracellular disposition of the plasmid. %26lt;br%26gt;Results: The enzymatic activity of the cells treated with the vectors increased significantly relative to the untreated cells, regardless of the formulation assayed. When the SLNs were prepared with protamine or dextran and protamine, the activity of the alpha-Gal A enzyme by the transfected Hep G2 cells increased up to 12-fold compared to that of untreated cells. %26lt;br%26gt;Conclusion: With this work we have revealed in Hep G2 cells the ability of a multicomponent system based on SLNs to act as efficient nonviral vectors to potentially correct low alpha-Gal A activity levels in FD with gene therapy.

• 出版日期2012-10-25